Novartis has undergone a series of transactions that now concentrate the company on three leading divisions with innovation power and worldwide scale: pharmaceuticals, eye care and generics.
Featured Posts
Although price restrictions and lowered reimbursements initially affected the company’s 2014 performance, Novo Nordisk reached one of its long-time pipeline goals with the resubmission and approval of Tresiba in the United States.
After the restructuring of its operations, one key divestment, the acquisition of Hospira and some encouraging pipeline advances, Pfizer executives believe the company is on track for a return to significant growth in the future.
With new CEO Olivier Brandicourt at the helm, launches of new products in 2014 and 2015, pipeline progression, R&D collaborations and the reorganization of the company into a new structure coming in 2016, Sanofi is setting the stage for the future.
Snubbed by its initial takeover target Mylan, Teva moved on by acquiring Allergan’s generic business instead.
Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials – In the extension of two Phase […]
How EMRs will – and won’t – change the brand conversation By Gabriel Cangiano, Director, HCP & Payer Strategies, Intouch Solutions [email protected] If electronic medical records didn’t already exist, […]
Merck and Pfizer collaborate with Dako in developing an immunohistochemistry (IHC)-based companion diagnostic (CDx) in immuno-oncology September 24, 2015 05:00 PM Eastern Daylight Time DARMSTADT, Germany & […]
-Pain intensity through 24 hours reduced by 69%-Pain intensity through 72 hours reduced by 40%-Time to first use of opiate rescue medication increased by 488%-32% of patients received no opiate […]
Incyte to pay Hengrui $25 million upfront plus the potential for milestone and royalty payments WILMINGTON, Del.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq: INCY) today announced a global license and collaboration agreement […]